{"DataElement":{"publicId":"3113591","version":"1","preferredName":"Patient Gynecologic Stage Grouping Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type as relating to an assessment based on the combined evaluation of a patient's T stage, M stage, and N stage of a malignant neoplasm arising from the health issues of women as a means to determine whether a patient/participant is suitable for enrollment in a study according to protocol criteria and procedures.","longName":"3113587v1.0:3113588v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3113587","version":"1","preferredName":"Patient Gynecologic Malignant Neoplasm Stage Grouping Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to an assessment based on the combined evaluation of a patient's T stage, M stage, and N stage a malignant neoplasm arising from the health issues of women as a means to determine whether a patient/participant is suitable for enrollment in a study according to protocol criteria and procedures.","longName":"2233604v1.0:3113585v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3113602","version":"1","preferredName":"Gynecologic Malignant Neoplasm Stage Grouping Clinical Trial Eligibility Criteria","preferredDefinition":"Of or relating to or practicing gynecology; pertaining to the health issues of women.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR):Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C28016:C9305:C38027:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gynecologic","conceptCode":"C28016","definition":"Of or relating to or practicing gynecology; pertaining to the health issues of women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89B7B363-6FB3-49E9-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"ONEDATA","dateModified":"2010-06-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"89B7B363-6F25-49E9-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3113588","version":"1","preferredName":"Patient Gynecologic Malignant Neoplasm Stage Grouping Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of stage grouping of a malignant neoplasm arising the health issues of women used to determine a patient/participant's eligibility to participate on a clinical trial.","longName":"3113588v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage II","valueDescription":"Stage II","ValueMeaning":{"publicId":"3114068","version":"1","preferredName":"Stage II","longName":"3114068","preferredDefinition":"The tumor has involved the corpus and the cervix (according to FIGO 1988 Stage Description)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89BA6748-3B92-9EA0-E040-BB89AD435C25","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E96BCE5-A538-4DF4-E040-BB89AD435EAA","beginDate":"2010-08-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","deletedIndicator":"No"},{"value":"Stage III","valueDescription":"Stage III","ValueMeaning":{"publicId":"3114065","version":"1","preferredName":"Stage III","longName":"3114065","preferredDefinition":"The tumor has extended outside the uterus but not outside the pelvis (according to FIGO 1988 Stage Description)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89BA6748-3B29-9EA0-E040-BB89AD435C25","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E96BCE5-A54E-4DF4-E040-BB89AD435EAA","beginDate":"2010-08-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","deletedIndicator":"No"},{"value":"Recurrent (chemonaive)","valueDescription":"Recurrent","ValueMeaning":{"publicId":"3133027","version":"1","preferredName":"Recurrent","longName":"3133027","preferredDefinition":"occurring again.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent","conceptCode":"C14173","definition":"Occurring again.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E96BCE5-A559-4DF4-E040-BB89AD435EAA","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E96BCE5-A572-4DF4-E040-BB89AD435EAA","beginDate":"2010-08-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","deletedIndicator":"No"},{"value":"Stage III less than or equal to 1.0cm","valueDescription":"Stage III less than or equal to 1.0cm","ValueMeaning":{"publicId":"3202937","version":"1","preferredName":"Stage III less than or equal to 1.0cm","longName":"3202937","preferredDefinition":"Stage III less than or equal to 1.0cm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E727F7D-AD8A-154D-E040-BB89AD4315DA","latestVersionIndicator":"Yes","beginDate":"2011-03-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E727F7D-ADA3-154D-E040-BB89AD4315DA","beginDate":"2011-03-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-14","modifiedBy":"ONEDATA","dateModified":"2011-03-14","deletedIndicator":"No"},{"value":"Stage III, Max Residual disease > 1cm","valueDescription":"Residual Disease or Disorder Stage III","ValueMeaning":{"publicId":"3113589","version":"1","preferredName":"Residual Disease or Disorder Stage III","longName":"3113589","preferredDefinition":"Remaining or left behind.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.: Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage III","conceptCode":"C27970","definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89B7B363-6F51-49E9-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89B7B363-6F6A-49E9-E040-BB89AD436777","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"ONEDATA","dateModified":"2010-06-23","deletedIndicator":"No"},{"value":"Stage IV","valueDescription":"Stage IV","ValueMeaning":{"publicId":"2974083","version":"1","preferredName":"Stage IV","longName":"2974083","preferredDefinition":"remote disease involving skeleton, soft tissues, distant lymph node groups, etc.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCDCEC7-ED7A-F214-E040-BB89AD435B1B","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89B7B363-6FA0-49E9-E040-BB89AD436777","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"ONEDATA","dateModified":"2010-06-23","deletedIndicator":"No"},{"value":"Stage III, Max Residual disease > 1.0cm","valueDescription":"Residual Disease or Disorder Stage III","ValueMeaning":{"publicId":"3113589","version":"1","preferredName":"Residual Disease or Disorder Stage III","longName":"3113589","preferredDefinition":"Remaining or left behind.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.: Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage III","conceptCode":"C27970","definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89B7B363-6F51-49E9-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E727F7D-ADB7-154D-E040-BB89AD4315DA","beginDate":"2010-06-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-14","modifiedBy":"ONEDATA","dateModified":"2011-03-14","deletedIndicator":"No"},{"value":"Stage III (Neo-Adjuvant therapy planned)","valueDescription":"Stage III (Neo-Adjuvant therapy planned)","ValueMeaning":{"publicId":"3265625","version":"1","preferredName":"Stage III (Neo-Adjuvant therapy planned)","longName":"3265625","preferredDefinition":"Stage III (Neo-Adjuvant therapy planned)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABD26100-DE7C-1B22-E040-BB89AD43787D","latestVersionIndicator":"Yes","beginDate":"2011-08-31","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ABD26100-DE95-1B22-E040-BB89AD43787D","beginDate":"2011-08-31","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-31","modifiedBy":"REBOYJ","dateModified":"2012-03-05","deletedIndicator":"No"},{"value":"Stage IB1, tumor size (maximum visible or palpable) <= 2cm","valueDescription":"Stage IB1","ValueMeaning":{"publicId":"3225630","version":"1","preferredName":"Stage IB1","longName":"3225630","preferredDefinition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0.  T1b1: Clinically visible lesion 4.0 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB1","conceptCode":"C28052","definition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0. (partially adapted from AJCC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A031E3D4-43F7-D527-E040-BB89AD43393F","latestVersionIndicator":"Yes","beginDate":"2011-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBD782AF-7A69-9976-E040-BB89AD435C77","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"ONEDATA","dateModified":"2012-03-22","deletedIndicator":"No"},{"value":"Stage IA2","valueDescription":"Stage IA2","ValueMeaning":{"publicId":"3225632","version":"1","preferredName":"Stage IA2","longName":"3225632","preferredDefinition":"A stage term referring to invasive cervical cancer and invasive lung cancer. For cervical cancer, it includes: T1a2, N0, M0.  T1a2: Tumor with stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA2","conceptCode":"C27984","definition":"A stage term referring to invasive cervical cancer and invasive lung cancer. For cervical cancer, it includes: T1a2, N0, M0.  T1a2: Tumor with stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A031E3D4-4441-D527-E040-BB89AD43393F","latestVersionIndicator":"Yes","beginDate":"2011-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-05","modifiedBy":"COOPERM","dateModified":"2018-07-02","changeDescription":"Updated definition to include criteria for lung per NCIt. 7.2.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBD782AF-7A74-9976-E040-BB89AD435C77","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"ONEDATA","dateModified":"2012-03-22","deletedIndicator":"No"},{"value":"Stage IA1, must be LVSI+","valueDescription":"Lymphovascular Involvement Positive Finding Stage IA1","ValueMeaning":{"publicId":"3420426","version":"1","preferredName":"Lymphovascular Involvement Positive Finding Stage IA1","longName":"3420426","preferredDefinition":"Of or relating to the lymphatic vessels.: To have a connection by participation or association or use; sharing in an activity or process.: An observation confirming something, such as the presence of a disease, condition, or microorganism.: A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1a1, N0, M0.  T1a1: Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphovascular","conceptCode":"C25561","definition":"Of or relating to the lymphatic vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage IA1","conceptCode":"C27983","definition":"A stage term referring to invasive cervical and lung cancer.  For cervical cancer, it includes: T1a1, N0, M0.  T1a1: Tumor with stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD782AF-7A84-9976-E040-BB89AD435C77","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBD782AF-7A9D-9976-E040-BB89AD435C77","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"ONEDATA","dateModified":"2012-03-22","deletedIndicator":"No"},{"value":"Stage II, Max Residual disease >1 cm","valueDescription":"Residual Disease or Disorder Stage II","ValueMeaning":{"publicId":"3402637","version":"1","preferredName":"Residual Disease or Disorder Stage II","longName":"3402637","preferredDefinition":"Residual Disease or Disorder Stage II","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA84738B-0494-3AC6-E040-BB89AD430726","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA95B60E-6FBA-BF6A-E040-BB89AD435AF2","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-06","modifiedBy":"ONEDATA","dateModified":"2012-03-06","deletedIndicator":"No"},{"value":"Recurrent","valueDescription":"RECURRENT DISEASE","ValueMeaning":{"publicId":"2568039","version":"1","preferredName":"RECURRENT DISEASE","longName":"2568039","preferredDefinition":"Recurrent disease","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6D4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-12","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-12","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3F85DFC-169D-2D6F-E040-BB89AD43138E","beginDate":"2013-01-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-23","modifiedBy":"ONEDATA","dateModified":"2013-01-23","deletedIndicator":"No"},{"value":"Stage IV, Neo-adjuvant planned","valueDescription":"Stage IV, Neo-adjuvant planned","ValueMeaning":{"publicId":"3402634","version":"1","preferredName":"Stage IV, Neo-adjuvant planned","longName":"3402634","preferredDefinition":"Stage IV, Neo-adjuvant planned","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA84738B-042B-3AC6-E040-BB89AD430726","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA84738B-0444-3AC6-E040-BB89AD430726","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"ONEDATA","dateModified":"2012-03-05","deletedIndicator":"No"},{"value":"Stage IV, Max Residual disease >1 cm","valueDescription":"Residual Disease or Disorder Stage IV","ValueMeaning":{"publicId":"3402635","version":"1","preferredName":"Residual Disease or Disorder Stage IV","longName":"3402635","preferredDefinition":"Residual Disease or Disorder Stage IV","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA84738B-044E-3AC6-E040-BB89AD430726","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA84738B-0467-3AC6-E040-BB89AD430726","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"ONEDATA","dateModified":"2012-03-05","deletedIndicator":"No"},{"value":"Stage II, Neo-adjuvant planned","valueDescription":"Stage II, Neo-adjuvant planned","ValueMeaning":{"publicId":"3402636","version":"1","preferredName":"Stage II, Neo-adjuvant planned","longName":"3402636","preferredDefinition":"Stage II, Neo-adjuvant planned","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA84738B-0471-3AC6-E040-BB89AD430726","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA84738B-048A-3AC6-E040-BB89AD430726","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"ONEDATA","dateModified":"2012-03-05","deletedIndicator":"No"},{"value":"Stage III, Neo-Adjuvant planned","valueDescription":"Stage III (Neo-Adjuvant therapy planned)","ValueMeaning":{"publicId":"3265625","version":"1","preferredName":"Stage III (Neo-Adjuvant therapy planned)","longName":"3265625","preferredDefinition":"Stage III (Neo-Adjuvant therapy planned)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABD26100-DE7C-1B22-E040-BB89AD43787D","latestVersionIndicator":"Yes","beginDate":"2011-08-31","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA84738B-04C3-3AC6-E040-BB89AD430726","beginDate":"2011-08-31","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"ONEDATA","dateModified":"2012-03-05","deletedIndicator":"No"},{"value":"Stage IB1- tumor size (maximum visible or palpable) <= 2cm","valueDescription":"Stage IB1","ValueMeaning":{"publicId":"3225630","version":"1","preferredName":"Stage IB1","longName":"3225630","preferredDefinition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0.  T1b1: Clinically visible lesion 4.0 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB1","conceptCode":"C28052","definition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0. (partially adapted from AJCC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A031E3D4-43F7-D527-E040-BB89AD43393F","latestVersionIndicator":"Yes","beginDate":"2011-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CB5615E9-087F-7C89-E040-BB89AD437143","beginDate":"2012-03-22","endDate":null,"createdBy":"OKPALOBV","dateCreated":"2012-10-05","modifiedBy":"ONEDATA","dateModified":"2012-10-05","deletedIndicator":"No"},{"value":"Stage IA1- must be LVSI+","valueDescription":"Lymphovascular Involvement Positive Finding Stage IA1","ValueMeaning":{"publicId":"3420426","version":"1","preferredName":"Lymphovascular Involvement Positive Finding Stage IA1","longName":"3420426","preferredDefinition":"Of or relating to the lymphatic vessels.: To have a connection by participation or association or use; sharing in an activity or process.: An observation confirming something, such as the presence of a disease, condition, or microorganism.: A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1a1, N0, M0.  T1a1: Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphovascular","conceptCode":"C25561","definition":"Of or relating to the lymphatic vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage IA1","conceptCode":"C27983","definition":"A stage term referring to invasive cervical and lung cancer.  For cervical cancer, it includes: T1a1, N0, M0.  T1a1: Tumor with stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD782AF-7A84-9976-E040-BB89AD435C77","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CB5615E9-086B-7C89-E040-BB89AD437143","beginDate":"2012-03-22","endDate":null,"createdBy":"OKPALOBV","dateCreated":"2012-10-05","modifiedBy":"ONEDATA","dateModified":"2012-10-05","deletedIndicator":"No"},{"value":">=1.0 cm","valueDescription":">=1.0 cm","ValueMeaning":{"publicId":"3870358","version":"1","preferredName":">=1.0 cm","longName":"3870358","preferredDefinition":">=1.0 cm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E517CCE5-EFFF-FA9D-E040-BB89AD435280","latestVersionIndicator":"Yes","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E517CCE5-F018-FA9D-E040-BB89AD435280","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"ONEDATA","dateModified":"2013-08-29","deletedIndicator":"No"},{"value":"<1.0 cm","valueDescription":"<1.0 cm","ValueMeaning":{"publicId":"3870359","version":"1","preferredName":"<1.0 cm","longName":"3870359","preferredDefinition":"<1.0 cm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E517CCE5-F022-FA9D-E040-BB89AD435280","latestVersionIndicator":"Yes","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E517CCE5-F03B-FA9D-E040-BB89AD435280","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"ONEDATA","dateModified":"2013-08-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"89B7B363-6F37-49E9-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"BRETTS","dateModified":"2013-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000172","version":"1","longName":"GOG-0241","context":"NRG"},{"publicId":"4104913","version":"1","longName":"GOG-0241","context":"NRG"},{"publicId":"4104897","version":"1","longName":"GOG-0250","context":"NRG"},{"publicId":"4104940","version":"1","longName":"GOG-0268","context":"NRG"},{"publicId":"4058120","version":"1","longName":"GOG-0278","context":"NRG"},{"publicId":"4104917","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000174","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000175","version":"1","longName":"GOG-0262","context":"NRG"}]}],"AlternateNames":[{"name":"3113587v1.0:3113588v1.0","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"CRF Text3","type":"Alternate Question Text","description":"What stage is the disease?","url":null,"context":"CTEP"},{"name":"What is the stage/residual di","type":"Preferred Question Text","description":"What is the stage/residual disease status","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Does the patient have either Stage II-IV disease (no brain metastasis) or recurrent Stage I disease (chemonaive)?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Does the patient have either Stage II-IV disease (new or recurrent- chemonaive, no brain metastasis) or recurrent Stage I disease (chemonaive)?","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Does the patient have advanced or recurrent uterine leiomyosarcoma with documented disease progression? Which one?","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Measurement of gross residual disease","url":null,"context":"CTEP"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"89B7B363-6F74-49E9-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-06-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}